Perry Nisen

Perry joined Sofinnova as Executive Partner in 2018. He is a physician scientist with extensive experience in drug discovery and development, focusing on later stage pre-clinical and clinical companies with particular interest in oncology, neuroscience and immunology/inflammation.

Until recently, Perry was CEO of the Sanford Burnham Prebys Medical Discovery Institute (SBP). As CEO, Perry was responsible for all aspects of the organization including strategy, operations and performance. Prior to SBP, he held multiple senior leadership positions during his tenure at GlaxoSmithKline (GSK) including SVP of Science and Innovation, interim Chief Medical Officer, and Oncology Therapy Area Head. When he was the Oncology Therapy Area Head, he was accountable for the Oncology portfolio from target to market and this division was subsequently acquired by Novartis for over $16B. Responsibilities at GSK included all aspects of drug discovery, clinical development, risk/benefit and operations. Before GSK, Perry was the Divisional Vice President, Cancer Research at Abbott Laboratories. Prior to industry, Perry was the Lowe Foundation Professor at the University of Texas Southwestern Medical Center.

Perry holds a BS from Stanford University, and MD/PhD from the Albert Einstein College of Medicine. Perry represents Sofinnova as Chairman of Quanta. He is also an independent Director of TEVA Pharmaceuticals, and chair of their science and technology committee.